Exxe Group’s M Meditech Division Reports Record Quarterly Results
Exxe Group’s M Meditech Division Reports Record Quarterly Results
---M Meditech revenue jumps by 55% & EBIT more than doubles compared with same period a year ago
-M Meditech收入增長55%,息税前利潤比去年同期增加一倍以上
---First half of fiscal 2023 results approaching the level achieved for the entire fiscal 2022 year
-2023財年上半年業績接近整個2022財年的水平
---M Meditech enjoyed strong growth in medical hygiene products to government and military segments
-M Meditech在面向政府和軍事部門的醫療衞生產品方面增長強勁
NEW YORK, NY / ACCESSWIRE / October 27, 2022 / Exxe Group, Inc. (OTC PINK:AXXA) , ("Exxe" or the "Company") a diversified fintech company, is pleased to announce that its M Meditech Division has a record quarterly revenue and EBIT growth for the Q2 period ended September 30, 2022. M Meditech is one of Exxe Group's core segments. Other Exxe top performers will be reporting financial results ahead of the Company's full quarterly report scheduled for mid-November.
紐約,NY/ACCESSWIRE/2022年10月27日/Exxe Group,Inc.(場外粉色:AXXA),(“埃克森”或“公司”)是一家多元化經營的金融科技公司,我們很高興地宣佈,在截至2022年9月30日的第二季度,M醫療技術部門的收入和息税前利潤都達到了創紀錄的水平。M Meditech是Exxe集團的核心業務之一。其他Exxe表現最好的公司將在公司定於11月中旬發佈完整季度報告之前報告財務業績。
Financial Highlights
財務亮點
M Meditech generated record quarterly revenue of $2,173,480 as compared with $1,402,034 for the same period a year ago, representing a 55% increase. EBIT of $1,271,411 was a 117.8% jump from the $583,606 recorded a year ago. Thus, EBIT for this quarter was nearly equivalent to the revenue generated in the September quarter of last year. On a profitability percentage basis, EBIT margin was 58.5% in this quarter a major increase from the 41.6% EBIT margin previously recorded.
M Meditech創造了創紀錄的季度收入2,173,480美元,而去年同期為1,402,034美元,增長了55%。息税前利潤為1,271,411美元,較一年前的583,606美元躍升117.8。因此,本季度的息税前利潤幾乎相當於去年9月季度的收入。在盈利百分比的基礎上,本季度息税前利潤為58.5%,比之前錄得的41.6%的息税前利潤率大幅增長。
Results on a sequential quarterly basis were also strong. Revenue was up 23.7% from the June 30 quarter while EBIT grew by 37.8%. EBIT margin rose to 58.5% from 47.4%.
按季度計算的業績也很強勁。收入比6月30日這個季度增長了23.7%,息税前利潤增長了37.8%。息税前利潤從47.4%上升到58.5%。
Interestingly, total sales and EBIT for the entire 2022 fiscal year were $5,249,606 and $2,560,434. Results for the first half of the current fiscal 2023 year are already at the $3,930,207 and $2,194,311 levels. Therefore, Exxe leadership is confident that the current full fiscal year results will be substantially greater than the figures recorded a year ago, especially EBIT.
有趣的是,整個2022財年的總銷售額和息税前利潤分別為5,249,606美元和2,560,434美元。本2023財政年度上半年的業績已經達到3930,207美元和2,194,311美元的水平。因此,Exxe領導層相信,當前整個財年的業績將大幅高於一年前的數字,特別是息税前利潤。
Business Highlights
業務亮點
M Meditech is Exxe's healthcare products division engaged in B2B distribution in Switzerland and Europe, including commercial, government, and military channels. Product sales during the quarter were led by its core medical hygiene offerings such as protective clothing, syringes, bandages, sterilization material, etc. During the period, the Company benefitted from industry trends such as demand from the military and government verticals. In addition, M Meditech enjoyed new customer growth and acquisition in the quarter, a trend likely to continue. With global supply chain delays a concern by customers, the Company recorded record sales demand and orders which also led to a big jump in EBIT margin. Growth in these channels and potential new B2C business could be reflected going forward as these supply chain concerns are not likely to be reduced in the near future.
M Meditech是Exxe的保健品部門,在瑞士和歐洲從事B2B分銷,包括商業、政府和軍事渠道。該季度的產品銷售主要得益於其核心醫療衞生產品,如防護服、注射器、繃帶、消毒材料等。在此期間,該公司受益於軍事和政府垂直市場的需求等行業趨勢。此外,M Meditech在本季度實現了新客户的增長和收購,這一趨勢可能會繼續下去。隨着客户對全球供應鏈延誤的擔憂,該公司錄得創紀錄的銷售需求和訂單,這也導致EBIT利潤率大幅躍升。這些渠道的增長和潛在的新B2C業務可能會在未來反映出來,因為這些供應鏈方面的擔憂在不久的將來不太可能減少。
Future Exxe Group News
未來Exxe集團新聞
Exxe plans to publish quarterly results for its key business segments and industries ahead of releasing full company financial results later next month. Management also plans to inform investors of its updated corporate roadmap, fintech platform, and technology tools positioning and related information in the coming weeks.
Exxe計劃在下月晚些時候發佈完整的公司財務業績之前,公佈其關鍵業務部門和行業的季度業績。管理層還計劃在未來幾周向投資者通報其更新的公司路線圖、金融科技平臺和技術工具定位及相關信息。
Dr. Eduard Nazmiev, Exxe Group CEO, commented on the strong M Meditech financial performance and upcoming publications. "We are very pleased with the back-to-back record quarterly financial results for M Meditech. It is especially impressive as the EBIT for the first half of the fiscal year is nearly the same level as EBIT recorded for this business for all of last year. We believe there is a hidden value to leverage in this business and others as we integrate technology tools and online transaction generation that have proven to serve as major growth drivers. The successfully executed Exxe vision remains centered on migrating and evolving our businesses to our technology-centric platforms and infrastructures. We look forward to providing our updated roadmap and positioning following our fiscal September 2023 results in mid-November."
Exxe集團首席執行官Eduard Nazmiev博士對M Meditech強勁的財務表現和即將出版的出版物發表了評論。我們對M Meditech連續創紀錄的季度財務業績感到非常滿意。這尤其令人印象深刻,因為本財年上半年的息税前利潤幾乎與去年全年這項業務的息税前利潤水平相同。我們相信,隨着我們整合已被證明是主要增長動力的技術工具和在線交易生成,這項業務和其他業務中有隱藏的價值可供利用。成功執行的Exxe願景仍然以將我們的業務遷移和發展為以技術為中心的平臺和基礎設施為中心。我們期待着在11月中旬我們2023財年9月的結果之後提供我們最新的路線圖和定位。“
About Exxe Group
關於Exxe集團
Exxe Group is a diversified fintech corporation focusing on acquisitions in the following sectors: real estate, interior design, automotive, medical, agribusiness, and financial services. Exxe Group is an acquisition-driven company. The Company's strategy is to acquire controlling equity interests in undervalued companies and undertake an active role in improving their performance - accelerating their growth by providing both access to capital and management expertise.
埃克森美孚集團是一家多元化的金融科技集團,專注於以下領域的收購:房地產、室內設計、汽車、醫療、農業綜合企業和金融服務。埃克森美孚是一家以收購為導向的公司。該公司的戰略是收購被低估公司的控股權,並在改善它們的業績方面發揮積極作用-通過提供獲得資本和管理專業知識的途徑來加速它們的增長。
For additional information please visit the Company's
欲瞭解更多信息,請訪問本公司的
Website:
網站:
Twitter:
推特:
Forward-Looking Statements:
前瞻性陳述:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.
本新聞稿包含符合修訂後的1933年證券法第27A節和修訂後的1934年證券交易法第21E節的前瞻性陳述。在某些情況下,您可以通過以下詞語來識別前瞻性陳述:“預期”、“相信”、“繼續”、“可能”、“估計”、“預期”、“打算”、“可能”、“正在進行”、“計劃”、“潛在”、“預測”、“項目”、“應該”、“將”、“將”或這些術語或其他類似術語的否定。儘管並不是所有前瞻性聲明都包含這些詞語。前瞻性陳述不是對未來業績或結果的保證,也不一定準確地説明實現這種業績或結果的時間或方式。前瞻性陳述以作出陳述時可獲得的信息為基礎,涉及已知和未知的風險、不確定因素和其他因素,這些風險、不確定性和其他因素可能會導致我們的結果、活動水平、業績或成就與本新聞稿中前瞻性陳述明示或暗示的信息大不相同。
CONTACT: Exxe Group IR: info@exxegroup.com
聯繫方式:電子郵件:Info@exxegroup.com
SOURCE: Exxe Group
資料來源:Exxe集團